Dylan Sturgeon
Procedural sedation in older patients presents unique challenges due to age-related changes in physiology and increased susceptibility to adverse events. Remimazolam, a novel ultra-short-acting benzodiazepine, has emerged as a promising agent for procedural sedation in this population. This article provides a systematic review and meta-analysis of existing literature to evaluate the efficacy and safety of remimazolam in older patients undergoing procedural sedation. Additionally, Trial Sequential Analysis (TSA) is employed to determine the robustness of current evidence and ascertain if further research is warranted.
Compartilhe este artigo
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Hindi 